TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2021.
PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022
Globe Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here